File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/jgh.12499
- Scopus: eid_2-s2.0-84897603558
- PMID: 24372662
- WOS: WOS:000331469400007
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment
Title | Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment |
---|---|
Authors | |
Keywords | Adefovir Antiviral Entecavir Lamivudine Telbivudine Tenofovir |
Issue Date | 2014 |
Publisher | Wiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH |
Citation | Journal of Gastroenterology and Hepatology, 2014, v. 29 n. 3, p. 428-434 How to Cite? |
Abstract | Oral nucleoside/nucleotide analogues (NAs) are the mainstay of therapy for patients with chronic hepatitis B, and are generally well tolerated. Despite this, the safety profile of NAs is of paramount importance since the majority of patients will require long-term treatment. All NAs can potentially affect human DNA polymerase with decrease in mitochondrial DNA, leading to manifestations of mitochondrial toxicity. As a class effect therefore, NAs can potentially cause extra-hepatic conditions such as myopathy, nephropathy, neuropathy, and lactic acidosis. Indeed, effects on muscles including myopathy and creatine kinase elevations have been described with clevudine and telbivudine use. Both adefovir and tenofovir are associated with dose-dependent nephropathy, predominantly affecting the proximal renal tubules. Neuropathy appears to be rare, and most commonly reported in patients receiving combination therapy with telbivudine and interferon. Increased risk of lactic acidosis has also been described for those with impaired liver and renal function taking entecavir. Loss of bone mineral density and hypophosphatemia has been described with the use of nucleotide analogues, although the overwhelming studies have been with HIV-infected patients. However, not all extra-hepatic effects are detrimental. Recent evidence has suggested a potential renal beneficial effect with the use of telbivudine. The effect of NAs on pregnancy appears to be minimal for all NAs, with telbivudine and tenofovir having a more favorable category B rating. Ongoing pharmacovigilance is essential to identify new and monitor existing extra-hepatic effects associated with NA use. |
Persistent Identifier | http://hdl.handle.net/10722/193876 |
ISSN | 2023 Impact Factor: 3.7 2023 SCImago Journal Rankings: 1.179 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fung, JYY | en_US |
dc.contributor.author | Seto, WKW | en_US |
dc.contributor.author | Lai, CL | en_US |
dc.contributor.author | Yuen, RMF | en_US |
dc.date.accessioned | 2014-01-28T06:30:44Z | - |
dc.date.available | 2014-01-28T06:30:44Z | - |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | Journal of Gastroenterology and Hepatology, 2014, v. 29 n. 3, p. 428-434 | en_US |
dc.identifier.issn | 0815-9319 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/193876 | - |
dc.description.abstract | Oral nucleoside/nucleotide analogues (NAs) are the mainstay of therapy for patients with chronic hepatitis B, and are generally well tolerated. Despite this, the safety profile of NAs is of paramount importance since the majority of patients will require long-term treatment. All NAs can potentially affect human DNA polymerase with decrease in mitochondrial DNA, leading to manifestations of mitochondrial toxicity. As a class effect therefore, NAs can potentially cause extra-hepatic conditions such as myopathy, nephropathy, neuropathy, and lactic acidosis. Indeed, effects on muscles including myopathy and creatine kinase elevations have been described with clevudine and telbivudine use. Both adefovir and tenofovir are associated with dose-dependent nephropathy, predominantly affecting the proximal renal tubules. Neuropathy appears to be rare, and most commonly reported in patients receiving combination therapy with telbivudine and interferon. Increased risk of lactic acidosis has also been described for those with impaired liver and renal function taking entecavir. Loss of bone mineral density and hypophosphatemia has been described with the use of nucleotide analogues, although the overwhelming studies have been with HIV-infected patients. However, not all extra-hepatic effects are detrimental. Recent evidence has suggested a potential renal beneficial effect with the use of telbivudine. The effect of NAs on pregnancy appears to be minimal for all NAs, with telbivudine and tenofovir having a more favorable category B rating. Ongoing pharmacovigilance is essential to identify new and monitor existing extra-hepatic effects associated with NA use. | en_US |
dc.language | eng | en_US |
dc.publisher | Wiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH | - |
dc.relation.ispartof | Journal of Gastroenterology and Hepatology | en_US |
dc.rights | The definitive version is available at www3.interscience.wiley.com | - |
dc.subject | Adefovir | - |
dc.subject | Antiviral | - |
dc.subject | Entecavir | - |
dc.subject | Lamivudine | - |
dc.subject | Telbivudine | - |
dc.subject | Tenofovir | - |
dc.title | Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment | en_US |
dc.type | Article | en_US |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | en_US |
dc.identifier.email | Seto, WKW: wkseto2@hku.hk | en_US |
dc.identifier.email | Lai, CL: hrmelcl@hku.hk | en_US |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | en_US |
dc.identifier.authority | Fung, JYY=rp00518 | en_US |
dc.identifier.authority | Seto, WKW=rp01659 | en_US |
dc.identifier.authority | Lai, CL=rp00314 | en_US |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1111/jgh.12499 | en_US |
dc.identifier.pmid | 24372662 | - |
dc.identifier.scopus | eid_2-s2.0-84897603558 | - |
dc.identifier.hkuros | 227482 | en_US |
dc.identifier.hkuros | 230537 | - |
dc.identifier.volume | 29 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 428 | - |
dc.identifier.epage | 434 | - |
dc.identifier.isi | WOS:000331469400007 | - |
dc.publisher.place | Australia | - |
dc.identifier.issnl | 0815-9319 | - |